PACB director granted 223,492 stock options

Pacific Biosciences of California director Marshall Mohr received a new stock option grant as equity compensation.

Rhea-AI Filing Summary

Pacific Biosciences of California director Marshall Mohr received a new stock option grant as equity compensation. The award covers 223,492 shares of common stock at an exercise price of $1.58 per share and increases his option holdings to 223,492 derivative securities.

The option vests in monthly installments over one year on the same day of the month as the grant date or, if earlier, on the date of the next annual stockholder meeting, as long as he continues serving as a director. The option expires on June 3, 2036, giving a long-dated incentive tied to the company’s share price performance.

Insights

Equity compensation analyst

Routine director stock option grant with time-based vesting.

Director Marshall Mohr was granted stock options for 223,492 shares of Pacific Biosciences of California common stock at an exercise price of $1.58. The transaction is coded as an acquisition grant, typical for board-level equity compensation.

The options vest monthly over one year, or earlier if the next annual stockholder meeting occurs sooner, contingent on continued board service. The expiration in 2036 creates a long incentive window, but the filing does not involve any open‑market buying or selling, so it carries limited signaling value about the director’s view of the stock.

Insider Trade Summary

Grant/Award: 223,492 shares

Grant/Award 1 txn

Insider MOHR MARSHALL

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	223,492	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 223,492 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option will vest monthly over one (1) year, on the same day of the month as the date of grant or, if earlier, on the date of the next annual meeting of the Company's stockholders occurring after the date of grant, provided such Reporting Person continues to serve as a director through the applicable vesting dates.

Key Figures

Option grant size: 223,492 shares Exercise price: $1.58 per share Holdings after grant: 223,492 derivative securities +2 more

5 metrics

Option grant size 223,492 shares Stock Option (right to buy) granted to director on June 3, 2026

Exercise price $1.58 per share Conversion or exercise price of stock option

Holdings after grant 223,492 derivative securities Total stock options following transaction

Expiration date June 3, 2036 Option expiration for this grant

Vesting schedule Monthly over 1 year Time-based vesting, or earlier at next annual meeting

Key Terms

Stock Option (right to buy), exercise price, vesting, expiration date, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 1.5800"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The shares subject to the option will vest monthly over one (1) year"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date: 2036-06-03T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

derivative securities financial

"derivativeTransactionCount: 1"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did PACB director Marshall Mohr receive in this Form 4 filing?

Marshall Mohr received a stock option grant for 223,492 shares of Pacific Biosciences common stock. The option is a compensation award, giving him the right to buy shares at a fixed exercise price if he remains a director as it vests.

What is the exercise price of Marshall Mohr’s new PACB stock options?

The new stock options have an exercise price of $1.58 per share. This means Mohr can buy Pacific Biosciences common stock at $1.58 once the options vest, regardless of the market price at that time, until the options expire.

How do the PACB stock options granted to Marshall Mohr vest?

The stock options vest in monthly installments over one year, starting from the grant date. Vesting may end earlier on the date of the next annual stockholder meeting, provided Mohr continues serving as a director through each applicable vesting date.

When do Marshall Mohr’s newly granted PACB stock options expire?

The stock options granted to Marshall Mohr expire on June 3, 2036. After that date, any unexercised options will lapse, and he will no longer be able to purchase Pacific Biosciences shares under this specific award.

Did Marshall Mohr buy or sell PACB shares in the market in this Form 4?

No, this Form 4 reports a grant of stock options, not an open‑market trade. The transaction code “A” reflects an acquisition through a grant or award as compensation, without any purchase or sale of existing Pacific Biosciences shares in the market.

How many PACB derivative securities does Marshall Mohr hold after this grant?

After this grant, Marshall Mohr holds 223,492 derivative securities related to Pacific Biosciences common stock. These represent stock options that can convert into shares if exercised after vesting and before their stated expiration date in 2036.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/04/2026 - 05:27 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MOHR MARSHALL

(Last) (First) (Middle)

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

1305 O'BRIEN DRIVE

(Street)

MENLO PARK CALIFORNIA 94025

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. [ PACB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.58	06/03/2026		A		223,492		07/03/2026(1)	06/03/2036	Common Stock	223,492	$0	223,492	D

Explanation of Responses:

1. The shares subject to the option will vest monthly over one (1) year, on the same day of the month as the date of grant or, if earlier, on the date of the next annual meeting of the Company's stockholders occurring after the date of grant, provided such Reporting Person continues to serve as a director through the applicable vesting dates.

Remarks:

	/s/ Brett Atkins, Attorney-in-fact	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)